Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2011

  1. IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis

    Journal of Neuroimmunology, Vol. 239, Núm. 1-2, pp. 101-104

  2. Pharmacogenomics and multiple sclerosis: Moving toward individualized medicine

    Current Neurology and Neuroscience Reports, Vol. 11, Núm. 5, pp. 484-491

  3. Replication of top markers of a genome-wide association study in multiple sclerosis in Spain

    Genes and Immunity, Vol. 12, Núm. 2, pp. 110-115

2010

  1. IFN-β pharmacogenomics in multiple sclerosis

    Pharmacogenomics, Vol. 11, Núm. 8, pp. 1137-1148

  2. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis

    Journal of Interferon and Cytokine Research, Vol. 30, Núm. 10, pp. 727-732

  3. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis

    Genes and Immunity, Vol. 11, Núm. 5, pp. 439-445